{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037733","form_type":"8-K/A","ticker":"SONM","cik":"0001178697","company_name":"DNA X, Inc.","filed_at":"2026-08-13T20:01:17+00:00","discovered_at":"2026-08-13T20:02:00.456439+00:00","generated_at":"2026-08-13T20:02:09.244338+00:00","sec_items":["3.02","8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"DNA X sells final Series B Preferred for $2.5M; pro forma equity $5.84M exceeds Nasdaq minimum","bullets":["On Aug 7, 2026, sold 416,667 Series B Preferred shares for $2.5M cash.","Pro forma stockholders' equity at Aug 7: $5.84M, above Nasdaq's $2.5M requirement.","Q1 2026 actual net income $6.34M; Q2 2026 est. net loss $1.53M; Aug 7 est. net loss $639k.","Adjustments include $4.946M financing, $3.049M note conversion, $963k reclass of redeemable shares.","Awaiting Nasdaq formal determination of compliance with Listing Rule 5550(b)(1)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037733","json":"https://secwatch.observer/filing/0001493152-26-037733.json","markdown":"https://secwatch.observer/filing/0001493152-26-037733.md","text":"https://secwatch.observer/filing/0001493152-26-037733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226037733/0001493152-26-037733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226037733/form8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:02:09.244338+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}